- From Hype to Integration: Rethinking Psychedelic Media in 2025 - June 27, 2025
The psychedelic conversation has fundamentally changed. At the 2025 Psychedelic Culture conference, this shift was palpable—we’re no longer debating whether these substances have legitimate uses, but rather how to thoughtfully integrate them into our existing systems. The old narrative framing of “counterculture versus mainstream” has become obsolete, replaced by the far more complex work of cultural, medical, and regulatory integration.
The battle to introduce the idea of psychedelics as potential therapeutic tools has largely been won. Most educated Americans now accept that compounds like psilocybin, MDMA, and ketamine, when used carefully with proper support, can offer meaningful benefits for certain conditions. This represents a remarkable shift from just a decade ago, when these substances were still widely dismissed as dangerous “party drugs” with no legitimate use. At that time, it was relatively easy to get stories published in mainstream news outlets about MDMA being explored for PTSD treatment, about military veterans seeking healing with psychedelic therapies, or about psilocybin helping people overcome end-of-life anxiety. Now, my journalist colleagues tell me, those stories have been written, and they’re looking for stories that are more nuanced.
Acceptance is just the beginning. The real challenge we face in 2025 is integration—embedding psychedelic medicines within systems that weren’t designed to accommodate them. During my graduate studies, I was deeply influenced by Michel Foucault’s insight that transformational change occurs precisely where dominant discourses fail to account for lived experience. I was also inspired by feminist scholar Donna Haraway’s argument that transformational change in science and medicine doesn’t occur through purely objective, detached discovery, but rather through situated, embodied, and highly contested processes that are deeply embedded in social, political, and historical contexts. Psychedelics exemplify this perfectly.
Our existing frameworks simply weren’t built to make sense of how these substances work:
- The pharmaceutical system expects individual drugs with clearly visible mechanisms of action, not complex experiential medicines
- Insurance models resist covering the therapy essential for safe and effective psychedelic treatment
- The Controlled Substances Act struggles to reconcile scheduling with legitimate research
- Our cultural vocabulary lacks adequate terminology to discuss expanded states of consciousness
This incongruence between systems and reality creates both tension and opportunity. We’re witnessing the friction of integration—and it’s in these spaces where genuine innovation emerges.
This incongruence between systems and reality creates both tension and opportunity. We’re witnessing the friction of integration—and it’s in these spaces where genuine innovation emerges.
The Post-Hype Reality and the Evolution of Media Coverage
We’ve officially moved beyond the “peak of inflated expectations” that characterized psychedelic coverage from 2020-2023. The FDA’s decision on MDMA-assisted therapy last August revealed just how challenging integration will be, even with compelling data and urgent need.
This period of adjustment—what technology analysts would call the “trough of disillusionment”—is precisely where industries mature. The projected growth in psychedelic medicine isn’t built on hype anymore, but on credible scientific results, sustainable business models, and the hard work of aligning these novel approaches with existing systems.
Ten or fifteen years ago, psychedelic journalism was largely the domain of writers with personal experience in these substances. Today, nearly every major outlet regularly covers psychedelic research and policy developments. This widening of coverage brings both opportunities and challenges.
While more media are covering psychedelics (nearly every major outlet has someone focused on psychedelic coverage), the depth of understanding hasn’t always kept pace. Many journalists have lacked the time or background knowledge needed to navigate these complex topics, resulting in reporting that either overhypes benefits or fixates exclusively on risks, missing the nuanced middle ground that actually serves readers.
What’s missing in much of today’s coverage is an understanding of the fundamental systems challenge. This isn’t just about approving new medications—it’s about reimagining how our healthcare, regulatory, and cultural frameworks can accommodate experiences that don’t fit neatly into existing categories.
Building Narrative Coalitions
Perhaps the most fascinating development I’m seeing is the emergence of what I call “narrative coalitions,” unlikely alliances forming around psychedelic medicine that transcend traditional political boundaries. Conservative politicians championing psychedelic therapy for veterans. Silicon Valley leaders combining optimization rhetoric with veteran advocacy. Traditional opponents of drug policy reform reconsidering their positions.
The ibogaine initiatives proposed in states like Texas and Kentucky exemplify this shift. These projects have brought together Republicans, Democrats, advocates, and medical professionals around shared goals of healing and recovery. When preparing veterans as spokespersons for these initiatives, our guidance has been straightforward: “speak your truth” and “no tie-dye in interviews.”
These coalitions form precisely because psychedelics expose the gaps in our existing systems. When veterans find healing through substances still classified as Schedule I drugs, it creates cognitive dissonance that demands resolution. When pharmaceutical companies struggle to develop protocols for drugs that require therapeutic support, it forces innovation. These friction points are where real change happens.
Discover the Indigenous Reciprocity Initiative of the Americas
Effective Communication Strategies
The most effective media strategies today focus on concrete, newsworthy developments while emphasizing the integration challenges through multiple channels:
- Scientific publications: Highlighting peer-reviewed research that advances our understanding of benefits and risks
- Legal and policy developments: Tracking the dozens of psychedelics-related bills introduced across more than a dozen states since early 2025
- Ethics: Addressing complex questions around therapist training, access, and integration
- High-profile incidents: Thoughtfully examining cases like Matthew Perry’s death and the Alaska Airlines pilot incident to understand their implications
- Compelling personal stories: Elevating the experiences of veterans, athletes, and chronic pain sufferers who have found healing
The stories that work best cut across ideological lines. They focus on shared values rather than divisive aspects. This approach has allowed psychedelic medicine to transcend traditional political boundaries, with prominent Republicans like Congressman Morgan Luttrell and former Texas Governor Rick Perry now advocating alongside longstanding progressive supporters.
The stories that work best cut across ideological lines. They focus on shared values rather than divisive aspects.
Concerns About Current Coverage
Despite progress, several troubling patterns persist in psychedelic media coverage:
- The binary coverage problem: Media tends toward either uncritical enthusiasm or fear-based rejection, missing the thoughtful middle ground where most value lies. This creates unrealistic public expectations in both directions.
- Depth issues in mid-tier coverage: As psychedelics become mainstream news, many outlets lack the specialized knowledge to cover them responsibly. The result is often superficial reporting that fails to explore the systems-level challenges of integration.
- Missing historical context: Few stories acknowledge Indigenous traditions or explain how prohibition disrupted decades of promising research. This omission perpetuates problematic power dynamics and misses an opportunity to educate about psychedelics’ rich historical context.
- Overemphasis on commercialization: Too many stories frame psychedelics primarily as market opportunities, creating pressure to rush development while potentially compromising safety standards. This approach alienates traditional communities that preserved these practices during prohibition.
The Path Forward: Integration, Not Just Introduction
According to Donna Haraway, transformational change in science and medicine happens when knowledge becomes more inclusive, reflexive, and responsive to power and difference. It is driven by hybrid thinking, challenges to authority, and the integration of marginalized perspectives into what counts as legitimate science. So, our collective task now is far more subtle than convincing people that psychedelics have potential value. It’s about the meticulous work of developing frameworks that allow these medicines to be safely and ethically integrated into our healthcare systems, legal structures, and cultural understanding.
This includes:
- Designing regulatory pathways that recognize the unique nature of psychedelic-assisted therapies, as psychedelics are the first new class of pharmaceuticals to enter the system since SSRIs in the late 1980s.
- Creating insurance models that cover both medication and necessary therapeutic support
- Developing training standards for practitioners across multiple disciplines
- Building public education that goes beyond simplistic messages about benefits or risks
- Establishing ethical guidelines that respect both scientific rigor and traditional wisdom
This is the transition we’re witnessing: from mainstreaming to integration. The introduction phase is largely complete. The integration phase—where these medicines find their proper place within our systems—is just beginning.
The introduction phase is largely complete. The integration phase—where these medicines find their proper place within our systems—is just beginning.
Despite the challenges, I remain profoundly optimistic. Cross-ideological coalitions continue to emerge. Some media outlets are developing increasingly sophisticated coverage. Our role as communicators is to push for more nuanced, responsible reporting that acknowledges both the potential and the complexity of this integration process.
The way forward isn’t always clear, but that’s to be expected. Like any productive psychedelic journey, it’s about staying present with what’s emerging and maintaining our commitment to healing.
Note: Brad Burge is founder and CEO of Integration Communications, which you can learn more about here.
Art by Mulinga.
Shop Our Latest T-Shirt Design, “Protecting Sacred Plants.”
Take a minute to browse our stock:
Did you enjoy reading this article?
Please support Chacruna's work by donating to us. We are an independent organization and we offer free education and advocacy for psychedelic plant medicines. We are a team of dedicated volunteers!
Can you help Chacruna advance cultural understanding around these substances?
Become a Chacruna Member
To make a direct donation click the button below:
